Nightingale Health

Nightingale’s new collaboration partner Innoquest Diagnostics is part of Pathology Asia, one of the largest diagnostic groups in Southeast Asia. This is the company’s first significant international customer relationship, where its technology is made available on a large scale to existing healthcare operators.

Nightingale’s growth journey has clearer guidelines thanks to revised strategy. Although the coming year will not yet be a turning point business wise for the company, the Terveystalo customer reference that is being built and new international reference that are sought still have conditions to generate evidence of successful commercial use of the company’s technology.

In the report, we are particularly interested in the recently announced expanding Terveystalo cooperation, the steps of the new strategy, and the progress of the Welltus cooperation. In terms of company figures, our attention is, in addition to the development of revenue in Japan, on the development of the cash position.

With the strategy update, the consumer business will end. We find this change sensible. In our view, the company’s previous strategy was to test different business models and identify the most potential ones for further investments.